Grufity logo
Grufity logo
ARTL

ARTL - Artelo Biosciences Inc Stock Price, Fair Value and News

$1.31+0.01 (+0.77%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

76/100

ARTL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

ARTL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ARTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARTL Price Action

Last 7 days

-3.0%

Last 30 days

-29.9%

Last 90 days

-73.4%

Trailing 12 Months

-94.0%

ARTL RSI Chart

ARTL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARTL Valuation

Market Cap

881.6K

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

62.97

Price/Free Cashflow

-0.11

ARTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ARTL Fundamentals

ARTL Revenue

Revenue (TTM)

14.0K

Rev. Growth (Yr)

-99.99%

Rev. Growth (Qtr)

100%

ARTL Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-24.7%

Earnings Growth (Qtr)

29%

ARTL Profitability

Return on Equity

-201.81%

Return on Assets

-107.57%

Free Cashflow Yield

-920.33%

ARTL Investor Care

Shares Dilution (1Y)

255.72%

Diluted EPS (TTM)

-30.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202614.0K---
20258.0K8.0K13.0K-
20223.0K4.0K3.0K2.0K
2021-1.6K2.0K2.0K
2020--1.0K1.2K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Artelo Biosciences Inc

ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
 CEO
 WEBSITEartelobio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

Artelo Biosciences Inc Frequently Asked Questions

ARTL is the stock ticker symbol of Artelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Artelo Biosciences Inc is 874.91 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ARTL's PE ratio (Price to Earnings) is -0.06 and Price to Sales (PS) ratio is 62.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARTL PE ratio will change depending on the future growth rate expectations of investors.